Fzata, Inc.
- Biotech or pharma, therapeutic R&D
Therapeutic Assets to Partner. FZ002 oral anti-toxin for C diff Infection, FIH P1 clinical trial in 2025. FZ006, oral anti-TNFa, multi-indications for mild, mod, severe IBD and abdominal pain. + preclinical pipeline of GI-related disease assets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}